Scaffolds That Mimic Antigen-presenting Cells Enable Ex Vivo Expansion of Primary T Cells

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2018 Jan 16

PMID 29334370

Citations 136

Authors

Alexander S Cheung

David K Y Zhang

Sandeep T Koshy

David J Mooney

Affiliations

Soon will be listed here.

Abstract

Therapeutic ex vivo T-cell expansion is limited by low rates and T-cell products of limited functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) and consists of a fluid lipid bilayer supported by mesoporous silica micro-rods. The lipid bilayer presents membrane-bound cues for T-cell receptor stimulation and costimulation, while the micro-rods enable sustained release of soluble paracrine cues. Using anti-CD3, anti-CD28, and interleukin-2, we show that the APC-mimetic scaffolds (APC-ms) promote two- to tenfold greater polyclonal expansion of primary mouse and human T cells compared with commercial expansion beads (Dynabeads). The efficiency of expansion depends on the density of stimulatory cues and the amount of material in the starting culture. Following a single stimulation, APC-ms enables antigen-specific expansion of rare cytotoxic T-cell subpopulations at a greater magnitude than autologous monocyte-derived dendritic cells after 2 weeks. APC-ms support over fivefold greater expansion of restimulated CD19 CAR-T cells than Dynabeads, with similar efficacy in a xenograft lymphoma model.

Citing Articles

Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.

Dana N, Dabiri A, Najafi M, Rahimi A, Ishaghi S, Shariati L Bioeng Transl Med. 2025; 10(2):e10716.

PMID: 40060757 PMC: 11883117. DOI: 10.1002/btm2.10716.

Heart-on-a-chip: a revolutionary organ-on-chip platform for cardiovascular disease modeling.

Liu B, Wang S, Ma H, Deng Y, Du J, Zhao Y J Transl Med. 2025; 23(1):132.

PMID: 39885522 PMC: 11780825. DOI: 10.1186/s12967-024-05986-y.

enhancement of CD8+ T cell activity using functionalized hydrogel encapsulating tonsil-derived lymphatic endothelial cells.

Hong H, Park C, Lee J, Kim K, Nath S, Oh M Theranostics. 2025; 15(3):850-874.

PMID: 39776798 PMC: 11700866. DOI: 10.7150/thno.100079.

Cytoskeleton-functionalized synthetic cells with life-like mechanical features and regulated membrane dynamicity.

Novosedlik S, Reichel F, van Veldhuisen T, Li Y, Wu H, Janssen H Nat Chem. 2025; 17(3):356-364.

PMID: 39754015 PMC: 11882449. DOI: 10.1038/s41557-024-01697-5.

Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity.

Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y Cancer Cell. 2024; 43(1):103-121.e8.

PMID: 39642888 PMC: 11756673. DOI: 10.1016/j.ccell.2024.11.003.

References

Meyer R, Sunshine J, Perica K, Kosmides A, Aje K, Schneck J . Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small. 2015; 11(13):1519-25. PMC: 4529071. DOI: 10.1002/smll.201402369. View

Koo H, Lee S, Na J, Kim S, Hahn S, Choi K . Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. Angew Chem Int Ed Engl. 2012; 51(47):11836-40. DOI: 10.1002/anie.201206703. View

Brentjens R, Riviere I, Park J, Davila M, Wang X, Stefanski J . Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118(18):4817-28. PMC: 3208293. DOI: 10.1182/blood-2011-04-348540. View

Li W, Lu B, Gu L, Choi Y, Kim J, Mooney D . The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration. Biomaterials. 2016; 83:249-56. PMC: 4754159. DOI: 10.1016/j.biomaterials.2016.01.026. View

Sunshine J, Perica K, Schneck J, Green J . Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials. 2013; 35(1):269-277. PMC: 3902087. DOI: 10.1016/j.biomaterials.2013.09.050. View

Alarcon B, Mestre D, Martinez-Martin N . The immunological synapse: a cause or consequence of T-cell receptor triggering?. Immunology. 2011; 133(4):420-5. PMC: 3143353. DOI: 10.1111/j.1365-2567.2011.03458.x. View

Hasan A, Selvakumar A, OReilly R . Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy. Adv Genet Eng. 2018; 4(3). PMC: 5891142. View

Imai C, Mihara K, Andreansky M, Nicholson I, Pui C, Geiger T . Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 18(4):676-84. DOI: 10.1038/sj.leu.2403302. View

Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril J, Clark D . Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother. 2004; 53(6):510-8. PMC: 11032822. DOI: 10.1007/s00262-003-0485-5. View

10.

Minguet S, Swamy M, Alarcon B, Luescher I, Schamel W . Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity. 2006; 26(1):43-54. DOI: 10.1016/j.immuni.2006.10.019. View

11.

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

12.

Jin C, Yu D, Hillerdal V, Wallgren A, Karlsson-Parra A, Essand M . Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Mol Ther Methods Clin Dev. 2015; 1:14001. PMC: 4362340. DOI: 10.1038/mtm.2014.1. View

13.

Rooney C, Smith C, Ng C, Loftin S, Sixbey J, Gan Y . Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998; 92(5):1549-55. View

14.

Fadel T, Steenblock E, Stern E, Li N, Wang X, Haller G . Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. Nano Lett. 2008; 8(7):2070-6. DOI: 10.1021/nl080332i. View

15.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

16.

Stronen E, Toebes M, Kelderman S, van Buuren M, Yang W, van Rooij N . Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016; 352(6291):1337-41. DOI: 10.1126/science.aaf2288. View

17.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

18.

Zappasodi R, Di Nicola M, Carlo-Stella C, Mortarini R, Molla A, Vegetti C . The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica. 2008; 93(10):1523-34. DOI: 10.3324/haematol.12521. View

19.

Cohen C, Gartner J, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky V . Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015; 125(10):3981-91. PMC: 4607110. DOI: 10.1172/JCI82416. View

20.

Perica K, Bieler J, Schutz C, Varela J, Douglass J, Skora A . Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano. 2015; 9(7):6861-71. PMC: 5082131. DOI: 10.1021/acsnano.5b02829. View